Chemical Structure
Inhibitor
1740 Citations
Palbociclib
BT-0017
Palbociclib is a highly selective CDK4/6 inhibitor approved for HR+/HER2- breast cancer. It arrests cells in the G1 phase.
Biological Activity
Prevents retinoblastoma (Rb) protein phosphorylation, blocking cell cycle progression from G1 to S phase.
Product Specifications
CAS Number571190-30-2
Molecular FormulaC24H29N7O2
Molecular Weight447.54 g/mol
TargetCDK4/6
PathwayCell Cycle
Disease AreaCancer
IC50/EC50/KdIC50: 11 nM (CDK4), 16 nM (CDK6)
Purity>99%
SolubilityDMSO: ≥25 mg/mL
Storage-20°C
SpeciesHuman
Available Sizes
| Size | Price | |
|---|---|---|
| 10 mg | $60.00 | |
| 50 mg | $210.00 |